Insights into the Interactions between Maleimide Derivates and GSK3β Combining Molecular Docking and QSAR

Molecular Dynamics of Protein Kinase-Inhibitor Complexes: A Valid Structural Information

(2012) Julio Caballero et al.   CURRENT PHARMACEUTICAL DESIGN

Synthesis, in silico, in vitro, and in vivo investigation of 5-[11C]methoxy-substituted sunitinib, a tyrosine kinase inhibitor of VEGFR-2

(2012) Julio Caballero et al.   EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY

Distinct expression and activity of GSK-3α and GSK-3β in prostate cancer

(2012) R. Siobhan Darrington et al.   INTERNATIONAL JOURNAL OF CANCER

GSK3: a key target for the development of novel treatments for type 2 diabetes mellitus and Alzheimer disease

(2012) Chong Gao et al.   REVIEWS IN THE NEUROSCIENCES

Binding Studies and Quantitative Structure-Activity Relationship of 3-Amino-1H-Indazoles as Inhibitors of GSK3β

(2011) Julio Caballero et al.   Chemical Biology & Drug Design

Further exploring rm2 metrics for validation of QSPR models

(2011) Probir Kumar Ojha et al.   CHEMOMETRICS AND INTELLIGENT LABORATORY SYSTEMS

Investigation of the Differences in Activity between Hydroxycycloalkyl N1 Substituted Pyrazole Derivatives As Inhibitors of B-Raf Kinase by Using Docking, Molecular Dynamics, QM/MM, and Fragment-BasedDe NovoDesign: Study of Binding Mode of Diastereomer Compounds

(2011) Julio Caballero et al.   Journal of Chemical Information and Modeling

A New Protocol for Predicting Novel GSK-3β ATP Competitive Inhibitors

(2011) Jiansong Fang et al.   Journal of Chemical Information and Modeling

Docking and quantitative structure–activity relationship studies for 3-fluoro-4-(pyrrolo[2,1-f][1,2,4]triazin-4-yloxy)aniline, 3-fluoro-4-(1H-pyrrolo[2,3-b]pyridin-4-yloxy)aniline, and 4-(4-amino-2-fluorophenoxy)-2-pyridinylamine derivatives as c-Met kinase inhibitors

(2011) Julio Caballero et al.   JOURNAL OF COMPUTER-AIDED MOLECULAR DESIGN

Study of differences in the VEGFR2 inhibitory activities between semaxanib and SU5205 using 3D-QSAR, docking, and molecular dynamics simulations

(2011) Camila Muñoz et al.   JOURNAL OF MOLECULAR GRAPHICS & MODELLING

Docking and quantitative structure–activity relationship studies for imidazo[1,2-a]pyrazines as inhibitors of checkpoint kinase-1

(2011) Julio Caballero et al.   MEDICINAL CHEMISTRY RESEARCH

GSK-3: Functional Insights from Cell Biology and Animal Models

(2011) Oksana Kaidanovich-Beilin et al.   Frontiers in Molecular Neuroscience

Computational Study on the Interaction of N1 Substituted Pyrazole Derivatives with B-Raf Kinase: An Unusual Water Wire Hydrogen-Bond Network and Novel Interactions at the Entrance of the Active Site

(2010) Jans H. Alzate-Morales et al.   Journal of Chemical Information and Modeling

Glycogen synthase kinase 3: more than a namesake

(2009) Geetha Vani Rayasam et al.   BRITISH JOURNAL OF PHARMACOLOGY

Potential Therapeutic Effect of Glycogen Synthase Kinase 3  Inhibition against Human Glioblastoma

(2009) K. Miyashita et al.   CLINICAL CANCER RESEARCH

Computational Study of the Interactions between Guanine Derivatives and Cyclin-Dependent Kinase 2 (CDK2) by CoMFA and QM/MM

(2009) Jans Alzate-Morales et al.   Journal of Chemical Information and Modeling

From a Natural Product Lead to the Identification of Potent and Selective Benzofuran-3-yl-(indol-3-yl)maleimides as Glycogen Synthase Kinase 3β Inhibitors That Suppress Proliferation and Survival of Pancreatic Cancer Cells

(2009) Irina N. Gaisina et al.   JOURNAL OF MEDICINAL CHEMISTRY

Glycogen synthase kinase 3 (GSK3) in the heart: a point of integration in hypertrophic signalling and a therapeutic target? A critical analysis

(2008) P H Sugden et al.   BRITISH JOURNAL OF PHARMACOLOGY

Maintenance of Constitutive I B Kinase Activity by Glycogen Synthase Kinase-3 /  in Pancreatic Cancer

(2008) W. Wilson et al.   CANCER RESEARCH